| Lourenco MT, Kennedy SH
Desvenlafaxine in the treatment of major depressive disorder. [Journal Article]
Neuropsychiatr Dis Treat 2009.:127-36.
Abstract | Full Citation | Find Related Articles | | Clayton AH, Kornstein SG, Rosas G, et al.
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. [Journal Article]
CNS Spectr 2009 Apr; 14(4):183-95.
Abstract | Full Citation | | Thase ME, Kornstein SG, Germain JM, et al.
An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. [Journal Article]
CNS Spectr 2009 Mar; 14(3):144-54.
Abstract | Full Citation | Find Related Articles | | Hollander E
Optimal dosing of desvenlafaxine, new insights in gambling and anorexia, and caffeine-induced psychosis. [Editorial]
CNS Spectr 2009 Mar; 14(3):116-7.
Full Citation | Find Related Articles | | Pae CU
Desvenlafaxine: a new antidepressant or just another one? [Journal Article, Research Support, Non-U.S. Gov't]
Expert Opin Pharmacother 2009 Apr; 10(5):875-87.
Abstract | Full Citation | | Feiger AD, Tourian KA, Rosas GR, et al.
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. [Journal Article]
CNS Spectr 2009 Jan; 14(1):41-50.
Abstract | Full Citation | Find Related Articles | | Archer DF, Dupont CM, Constantine GD, et al.
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. [JOURNAL ARTICLE]
Am J Obstet Gynecol 2009 Jan 22.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Laustsen G, Carrillo F, Johnson J, et al.
Drug approvals: '08 in review. Desvenlafaxine (Pristiq). [Journal Article]
Nurse Pract 2009 Feb; 34(2):28.
Full Citation | Publisher Full Text | Find Related Articles | | Preskorn S, Patroneva A, Silman H, et al.
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. [Journal Article]
J Clin Psychopharmacol 2009 Feb; 29(1):39-43.
Abstract | Full Citation | Find Related Articles | | Pae CU, Park MH, Marks DM, et al.
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. [Journal Article]
Curr Opin Investig Drugs 2009 Jan; 10(1):75-90.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
